News und Analysen
EQS-News: Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
EQS-News: Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
EQS-News: Final regulatory approval for voluntary public takeover offer – Strategic partnership between CVC and CompuGroup Medical takes effect upon completion of the offer
EQS-News: Final regulatory approval for voluntary public takeover offer – Strategic partnership between CVC and CompuGroup Medical takes effect upon completion of the offer
EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
EQS-News: Political tailwind for Verbio: German coalition agreement sets the course for fraud prevention, climate protection and energy security
EQS-News: Political tailwind for Verbio: German coalition agreement sets the course for fraud prevention, climate protection and energy security
EQS-News: Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
EQS-News: Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
Infineon further strengthens its number one position in automotive microcontrollers and boosts systems capabilities for software-defined vehicles with acquisition of Marvell’s Automotive Ethernet business
Infineon Technologies AG (FSE: IFX / OTCQX: IFNNY) is accelerating the build-up of its system capabilities for software-defined vehicles with the acquisition of Marvell Technology’s Automotive
EQS-News: Eckert & Ziegler: Record year 2024 with new all-time highs
EQS-News: Eckert & Ziegler: Record year 2024 with new all-time highs
EQS-News: Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
EQS-News: Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
EQS-News: Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
EQS-News: Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
EQS-News: CGM reports FY 2024 financials in line with revised guidance and expects to return to growth path in 2025
EQS-News: CGM reports FY 2024 financials in line with revised guidance and expects to return to growth path in 2025
EQS-Adhoc: Ad-hoc: CompuGroup Medical SE & Co. KGaA intends to reduce the annual dividend for the financial year 2024 to the legal minimum
EQS-Adhoc: Ad-hoc: CompuGroup Medical SE & Co. KGaA intends to reduce the annual dividend for the financial year 2024 to the legal minimum
EQS-News: Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for Radioisotope Supply and Contract Development and Manufacturing of Bicycle Radio Conjugates
EQS-News: Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for Radioisotope Supply and Contract Development and Manufacturing of Bicycle Radio Conjugates
EQS-News: Eckert & Ziegler Ensures Business Continuity After Cyber-Attack
EQS-News: Eckert & Ziegler Ensures Business Continuity After Cyber-Attack
EQS-News: Final results of voluntary public takeover offer – CVC has secured 21.85% of total share capital and voting rights of CompuGroup Medical
EQS-News: Final results of voluntary public takeover offer – CVC has secured 21.85% of total share capital and voting rights of CompuGroup Medical
EQS-Adhoc: Eckert & Ziegler Affected by Cyber Attack
EQS-Adhoc: Eckert & Ziegler Affected by Cyber Attack
EQS-News: Significant EBITDA recovery in Q2 2024/25 compared to previous quarter
EQS-News: Significant EBITDA recovery in Q2 2024/25 compared to previous quarter
EQS-News: Strong FY 2024 performance: Revenue up by 9 % YoY and exceeded guidance range, Enterprise Revenue grows by 26 % YoY, and Adjusted EBITDA Margin reaches 44 %
EQS-News: Strong FY 2024 performance: Revenue up by 9 % YoY and exceeded guidance range, Enterprise Revenue grows by 26 % YoY, and Adjusted EBITDA Margin reaches 44 %
EQS-News: Eckert & Ziegler SE: IT Incident Affects Eckert & Ziegler SE's Communication Channels
EQS-News: Eckert & Ziegler SE: IT Incident Affects Eckert & Ziegler SE's Communication Channels
EQS-News: Successful conclusion of initial acceptance period of CVC offer for CompuGroup Medical – Additional acceptance period from 29 January to 11 February 2025
EQS-News: Successful conclusion of initial acceptance period of CVC offer for CompuGroup Medical – Additional acceptance period from 29 January to 11 February 2025
EQS-Adhoc: Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase in Sales and Adjusted EBIT
EQS-Adhoc: Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase in Sales and Adjusted EBIT
EQS-News: CVC exceeds minimum acceptance threshold for voluntary public tender offer for CompuGroup Medical – additional acceptance period expected to commence on 29 January
EQS-News: CVC exceeds minimum acceptance threshold for voluntary public tender offer for CompuGroup Medical – additional acceptance period expected to commence on 29 January
EQS-Adhoc: Verbio SE: Verbio reduces EBITDA forecast for 2024/25; expectation of net financial debt of max. EUR 190 million unchanged
EQS-Adhoc: Verbio SE: Verbio reduces EBITDA forecast for 2024/25; expectation of net financial debt of max. EUR 190 million unchanged
EQS-Adhoc: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
EQS-Adhoc: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement